Literature DB >> 26634305

Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.

Vendel Kristensen1,2, Gunn Helen Malmstrøm1, Viggo Skar1, Arne Røseth3, Bjørn Moum2,4.   

Abstract

OBJECTIVE: Faecal (f-) calprotectin is a biomarker of intestinal inflammation. Previous studies have described intra-individual day-to-day variability of this biomarker in patients with inflammatory bowel disease (IBD) and morning samples have been suggested for standardisation purposes. With this project, we investigated if day-to-day variability differed from diurnal variability. Additionally, we evaluated a new extraction method for f-calprotectin analysis.
METHODS: Fifty patients provided three faeces samples from morning - evening - morning on two consecutive days. Nineteen patients provided two faeces samples from the same bowel movement, one conventional spot sample, and one sample with a device for patient-administered sampling and extraction.
RESULTS: The two morning samples differentiated between mucosal inflammation and mucosal healing with same level of agreement as the two samples from the same day (kappa 0.76), using an f-calprotectin cut-off level of 259 μg/g. Although large intra-individual variation in f-calprotectin values, there were no significant day-to-day (p = 0.096) or diurnal variation (p = 0.78). Used by laboratory technicians, the new extraction device correlated significantly with the conventional extraction method (p < 0.001), Spearman's rank correlation coefficient 0.95. Of the 19 patients testing patient administered extraction, two patients provided samples leading to considerably higher f-calprotectin levels than conventional sampling procedure.
CONCLUSIONS: The reliability of f-calprotectin morning samples is equal to the reliability of samples from different bowel movements on the same day. The new extraction method is reliable when used by laboratory technicians, but larger studies are recommended to evaluate patient administered extraction.

Entities:  

Keywords:  Biological markers; Crohn disease; enzyme-linked immunosorbent assay; faeces; inflammatory bowel diseases; leukocyte L1 antigen complex; ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 26634305     DOI: 10.3109/00365521.2015.1117650

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

Review 1.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

2.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

3.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

4.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.

Authors:  Vendel Kristensen; Arne Røseth; Tahir Ahmad; Viggo Skar; Bjørn Moum
Journal:  Gastroenterol Res Pract       Date:  2017-10-31       Impact factor: 2.260

5.  Faecal calprotectin determination: impact of preanalytical sample treatment and stool consistency on within- and between-method variability.

Authors:  Gordana Juricic; Tina Brencic; Andrea Tesija-Kuna; Milena Njegovan; Lorena Honovic
Journal:  Biochem Med (Zagreb)       Date:  2019-02-15       Impact factor: 2.313

6.  Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.

Authors:  Rasmus Goll; Richard Heitmann; Øystein Kittel Moe; Katrine Carlsen; Jon Florholmen
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

7.  A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.

Authors:  R Gacesa; A Vich Vila; V Collij; Z Mujagic; A Kurilshikov; M D Voskuil; E A M Festen; C Wijmenga; D M A E Jonkers; G Dijkstra; J Fu; A Zhernakova; F Imhann; R K Weersma
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.